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The complex nature of the patients who
require permanent vascular access makes it essen-
tial that a comprehensive, multidisciplinary
approach be adopted.1 The creation and mainte-
nance of functioning access and the associated
complications are responsible for significant mor-
bidity, hospitalization, and cost for patients with
end-stage renal disease. Good judgment for
access-site selection, technical surgical excellence,
and appropriate management of complications are
the primary objectives for long-term success.
However, other factors, such as regular vascular
laboratory surveillance postoperatively and central
coordination by a dedicated access coordinator for
seamless communication among nephrologists,
surgeons, and radiologists, are equally important
in ensuring a practical and cost-effective access
program.2,3
The long-term results and predictors of success
for vascular access at The Toronto Hospital were
studied. We describe the access program and empha-
size the role of the vascular access coordinator.
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Purpose: The long-term results and predictors of success for vascular access at The
Toronto Hospital were studied. This report describes the access program and emphasizes
the role of the vascular access coordinator.
Methods: A total of 384 consecutive patients underwent 466 vascular access procedures.
The access program is centered around a dedicated, full-time vascular access coordinator,
who is a registered nurse and is responsible for all aspects of access care, including follow-
up. Outcome variables were collected prospectively. Primary, primary-assisted, and sec-
ondary success was determined by means of Kaplan-Meier analysis, and the stepwise Cox
proportional hazards model was used for multivariate analysis of the factors that were
independently predictive of primary success.
Results: There were 235 autogenous arteriovenous fistulae (AVFs) and 231 arteriove-
nous grafts (AVGs). The cumulative primary, assisted-primary, and secondary success
(patent and functional for effective dialysis) at 24 months for all 466 cases combined
was 36% ± 3%, 54% ± 3%, and 66% ± 3%, respectively. The primary success for AVFs and
AVGs at 2 years was 54% ± 4% and 18% ± 4%, respectively (P < .001; log-rank test); the
primary-assisted success for AVFs and AVGs at 2 years was 62% ± 4% and 44% ± 6%,
respectively (P < .001; log-rank test); and the secondary success for AVFs and AVGs at
2 years was 70% ± 4% and 60% ± 5%, respectively (P = .331; log-rank test). Stratification
of variables revealed significant benefit for AVFs (P = .001), the female sex (P = .014),
and the absence of diabetes mellitus (P = .001). Multivariate analysis with Cox regres-
sion determined that access type (AVF vs AVG; P = .001) and diabetes mellitus (P =
.024) were independently predictive of primary success. The improved clinical coordi-
nation of access patients with the initiation of the vascular access program resulted in a
significant reduction in length of hospital stay before and after the program was orga-
nized (2.5 ± 0.06 vs 1.1 ± 0.03 days; P = .001). 
Conclusion: The organization of a vascular access program in a practical and cost-effec-
tive way for reduced length of hospital stay is streamlined through a dedicated access
coordinator, who ensures an integrated, multidisciplinary approach. The results for the
Cox model is useful when discussing the anticipated results of access procedures with
individual patients. (J Vasc Surg 1999;30:727-33.)
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METHODS
Demographic data and outcome variables were
collected on 384 consecutive patients who under-
went 466 vascular access procedures for hemodialy-
sis, excluding insertion of central venous catheters,
at The Toronto Hospital during a 2-year period
from January 1, 1996, to December 31, 1997. All
patients and the status of their access were observed
by a dedicated, full-time vascular access coordinator,
a registered nurse who was responsible for access
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Table I. Vascular access care guide at The Toronto Hospital
Date Outpatient preparation phase SDD Recovery and follow-up
(1) Patient outcomes •Patient/family oriented •Able to demonstrate 
to episode of care how to check for bruit
•Verbalizes an awareness of •Able to verbalize the care 
–Preoperative routine of an arteriovenous access
–What arteriovenous access is •Able to verbalize whom 
–Necessity for hemodialysis to call if there is a problem
–Difference between fistula and graft with the access
–Potential complications
–How to care for fistula or graft
–Swollen arm
(2) Teaching Dialysis vascular •Reinforce care of
access coordinator •Perfusion of hand access and how to 
•Creation of arteriovenous •Bruit check check bruit OD
fistula or graft pamphlet •Dressing, dry •Teach patient exercises
given to patient and intact to help mature fistula
•Teach patient and family •Reinforce no •Inform patient about what
all the information B/Ps or IVs to do if access clots 
needed to obtain the and whom to call
desired patient outcomes
(3) Discharge planning •Preadmit—length of •Clip removal 10 to 14
stay discussed with patient/ days or removed 
family and discharge during dialysis 2 weeks 
plan documented after surgery
•Referral to home care,
when required
•Instructed on care of
incision after surgery
•Instructed on whom to
contact if there are concerns
(4) Interventions
(a) Assessment/monitoring •VS B/P
•Bruit check q 
15 min to q 1 h
•Distal circulation
check q 1 h
(b) Treatments Observe dressing Clip removal at 
10 to 14 days 
after surgery, usually 
done in the clinic
(c) Tests Venograms, when required
(d) Medications After surgery
Ancef 1 gm IV
(e) Nutrition
(f) Activity •As tolerated Encourage to 
after surgery use arm for ADL, but to
•Keep graft arm avoid activities that may 
elevated when resting compromise the access
to minimize swelling
(g) Consults •Anesthesia consult 
usually with NP
•Endocrine consult for 
all patients with 
diabetes mellitus
SDD, Same-day discharge; IV, intravenous; q, every; ADL, activities of daily living; NP, nurse practitioner.
surveillance, identification of complications, orga-
nizing access interventions, and recording continued
success or failure of an individual access site. When
vascular access is required, the nephrologists com-
plete the initial medical evaluation and preadmission
paperwork and are responsible for management of
the comorbid conditions. The nurse coordinator
and the vascular surgeon conduct a weekly vascular
access clinic, at which the optimal access site is
planned, the consent obtained, and surgery sched-
uled. During this visit, the nurse coordinator edu-
cates new patients on all aspects of their surgery and
access care (Table I).
Algorithm for selection of vascular access type
and site. The types and distribution of the vascular
access procedures performed are listed in Table II.
Our algorithm begins with the nondominant arm.
The order for selection is from distal to proximal, to
preserve proximal sites. When there is a good radial
pulse and an acceptable cephalic vein is present in
the forearm (visible through skin with or without
proximal tourniquet), the procedure of choice is an
end-to-side cephalic vein to radial artery fistula.
When either is not available, but there is a good
cephalic vein in the upper arm, we would perform an
end-to-side cephalic vein to brachial artery fistula.
The basilic vein is not a good choice for an upper-
arm fistula, because its depth makes it difficult to
cannulate. However, an option is to transpose the
basilic vein to a more superficial location. When no
autogenous vein is available for a fistula, we feel for
a radial pulse and presence of vein in the antecubital
fossa, and a straight forearm polytetrafluoroethylene
(PTFE) graft is constructed from the radial artery to
the antecubital fossa. When the radial pulse is weak
or absent, but a vein is available in the antecubital
fossa, a forearm loop PTFE graft is constructed from
the brachial artery down and back to the antecubital
fossa. When there is no vein available in the antecu-
bital fossa, a straight upper-arm PTFE graft is con-
structed from the brachial artery to the axillary vein.
When no further revisions are feasible, the same
algorithm is used on the dominant arm. 
Vascular laboratory surveillance. Access sur-
veillance with Duplex scanning is performed every 6
months for all arteriovenous grafts (AVGs) or soon-
er, whenever indicated for a problem that arises. The
problems that would initiate an urgent assessment
are: (1) high venous pressures (more than 250 mm
Hg at a 400 mL/min pump speed); (2) difficult can-
nulation; and (3) less than 700 mL/min flow rate, as
determined with a Transonic flowmeter. The graft is
imaged by means of the Acuson XP 128 with a 5-
MHz linear probe. The peak systolic and end dias-
tolic velocity waveforms are obtained at the arterial
anastomosis, midgraft, and the venous anastomosis.
A moderate stenosis is defined as a peak systolic
velocity that has doubled relative to the normal peak
systolic velocity in a normal segment of the graft,
and a severe stenosis occurs when the peak systolic
velocity has tripled. In addition to stenoses, the
technologist notes any pseudoaneurysms that have
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Table II. Types and distribution of vascular access
procedures performed
Type Number
AVF (radiocephalic) 154 (33%)
AVF (upper arm) 85 (18%)
AVG (straight, forearm) 96 (21%)
AVG (loop, forearm) 49 (11%)
AVG (upper arm) 70 (15%)
Other (lower extremity, etc) 12 (3%)
AVF, Autogenous arteriovenous fistula; AVG, prosthetic arterio-
venous graft.
Fig 1. Cumulative primary (12 months, n = 162; 24
months, n = 53), primary-assisted (12 months, n = 162;
24 months, n = 55), and secondary success (patent and
effective dialysis; 12 months, n = 162; 24 months, n = 72)
for all 466 vascular access procedures combined (only data
with an SE less than 10% are shown).
Fig 2. Cumulative primary success for arteriovenous fis-
tulae (12 months, n = 90; 24 months, n = 40) vs arteri-
ovenous grafts (12 months, n = 72; 24 months, n = 15;
only data with an SE less than 10% are shown).
been imaged. Once an AVG has undergone an inter-
vention (ie, balloon angioplasty or thrombolysis),
the surveillance schedule is shortened to every 3
months, because of the higher risk for restenosis. A
“threatened” graft is defined as one with a severe
stenosis determined by means of the Duplex criteria
given. These would be confirmed with angiography,
and an intervention would be carried out when indi-
cated. A moderate stenosis would undergo Duplex
imaging again in 6 weeks. 
Autogenous arteriovenous fistulae (AVFs) are not
routinely scanned, because the turbulent flow at these
sites generally makes interpretation difficult. They are
only scanned when an access problem, as described, is
encountered. This is usually followed by a fistulagram
to determine if improvement can be achieved. 
Statistical analysis. Data were analyzed with
commercially available software (SYSTAT).4 Follow-
up was complete in all patients (median, 8 months;
mean, 11.6 months; range, 1 to 101.6 months). The
cumulative primary, assisted-primary, and secondary
access success was determined by means of the
Kaplan-Meier method.5 An individual access was
considered a success not only when patent, but also
when effective hemodialysis could be performed.
Therefore, an autogenous AVF that was patent, but
failed to mature into a functional access site was con-
sidered a failure. The relationship among seven vari-
ables and primary success was analyzed with both
univariate (Kaplan-Meier) and multivariate (Cox
regression6) statistical techniques. For each variable,
the Kaplan-Meier method was used as a means of
determining the cumulative percent primary success,
and the log-rank test was used as a means of specify-
ing statistical differences between subgroups.7 The
stepwise Cox proportional hazards model was used
for multivariate analysis of the factors that were inde-
pendently predictive of primary success.6
Length of stay. To determine whether the
access program affected the streamlining of access
care for the length of hospital stay, we compared the
length-of-stay before (in 1994, 191 cases and in
1995, 205 cases; total “before,” 396 cases) and after
(in 1997, 240 cases and in 1998, 252 cases; total
“after,” 492 cases) the program was implemented.
Data was not included for 1996 (212 cases), because
the program began in April 1996 and was not at
optimal operation for several months. 
RESULTS
A total of 466 vascular access procedures were
performed on 384 patients in the 2-year period
between January 1, 1996, and December 31, 1997,
by five surgeons. The average number of cases per-
formed by each surgeon was 93.2 (range, 20 to
170). The median age of the patients at the time of
access creation was 59 years; 40% of the patients had
diabetes mellitus; 60% of the patients were men, and
40% of the patients were women. The perioperative
morbidity for these procedures was low and is sum-
marized in Table III. In total, 235 autogenous AVFs
and 231 AVGs were performed. Of the 235 AVFs
performed, 11.5% did not mature sufficiently to be
useful for dialysis within 6 months. All prosthetic
vascular access was performed with 6-mm diameter,
regular wall thickness PTFE. It is noteworthy that
62% of the access procedures in men were autoge-
nous AVFs, compared with only in 33% of those in
women (P < .05). Seventy percent of the procedures
were performed with local anesthesia plus sedation,
19% were performed with local anesthesia alone, and
11% were performed with general anesthesia. 
Cumulative primary, assisted-primary, and sec-
ondary success The cumulative primary, assisted-pri-
mary, and secondary success (patent and functional
for effective dialysis) at 2 years for all 466 cases com-
bined was 36% ± 3%, 54% ± 3%, and 66% ± 3%, respec-
tively (Fig 1). The primary success for AVFs and
AVGs at 2 years was 54% ± 4% and 18% ± 4%, respec-
tively (P < .001; log-rank test; Fig 2); the primary-
assisted success for AVFs and AVGs at 2 years was 62%
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Fig 3. Cumulative primary-assisted success for arteriove-
nous fistulae (12 months, n = 90; 24 months, n = 47) vs
arteriovenous grafts (12 months, n = 72; 24 months, n =
17; only data with an SE less than 10% are shown).
Table III. Morbidity for 466 vascular access proce-
dures
Complication Number
Nil 443 (95.1%)
Aneurysm 1 (0.2%)
Infection (conservative) 10 (2.1%)
Infection (removal) 1 (0.2%)
Steal (conservative) 5 (1.1%)
Steal (ligation) 2 (0.4%)
Significant hematoma 4 (0.9%)
± 4% and 44% ± 6%, respectively (P < .001; log-rank
test; Fig 3), but there was no significant difference in
secondary success for AVFs and AVGs at 2 years (70%
± 4% and 60% ± 5%, respectively; P = .331; log-rank
test). It is noteworthy that 28.6% of AVGs underwent
attempts for secondary patency, compared with only
14% of AVFs. The results for the various types and dis-
tribution of access procedures are shown in Fig 4.
Table IV summarizes the univariate analysis of
seven variables and their association with primary
success (Kaplan-Meier); sex, presence of diabetes
mellitus, and access type (AVF vs AVG) were signifi-
cant after stratification (log-rank test). To eliminate
the potential confounding effect of univariate analy-
sis, the stepwise Cox proportional hazards model was
used for multivariate analysis. The factors that were
independently predictive of primary success were
access type (AVF vs AVG; P = .001) and the presence
or absence of diabetes mellitus (P = .024). The final
model and the four combinations were able to pre-
dict success (P = .001) and are shown in Fig 5.
Length of stay. The overall benefit of the access
program was to “streamline” the care of these patients,
with improved liaison and communication among sur-
geons, nephrologists, and interventional radiologists.
There was a significant reduction in length of hospital
stay after the initiation of the program, from 2.5 ±
0.06 days before (1994 and 1995) to 1.1 ± 0.03 days
after (1997 and 1998; P = .001; t test).
DISCUSSION
The hemodialysis population at The Toronto
Hospital at any one time totals approximately 400
patients, 340 of whom undergo dialysis on-site, and
60 of whom are on home dialysis or undergo dialysis
in free-standing units that our access program sup-
ports. Most patients stay within our program, with an
attrition rate of approximately 30 to 40 patients who
are transferred to other units, freeing space for new
patients, every 6 months. A large program such as
this is only possible through central coordination by
a dedicated, registered nurse coordinator whose
responsibilities include not only preparing for and
scheduling new access procedures, but also trou-
bleshooting all problems related to existing access
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Table IV. Univariate analysis of variables and their
association with success (Kaplan-Meier) and the
results when significant differences are observed 
Variable 2-year primary success P value
Age (59 years or .122
older or younger
than the median)
Sex Men, 43% ± 4%
Women, 26% ± 5% .014
Diabetes mellitus No, 42% ± 4%
Yes, 22% ± 5% .001
Connective tissue .118
disease (yes vs no)
AVF vs AVG AVF, 54% ± 4%
AVG, 18% ± 4% .001
Side (right vs left) .742
Anesthetic .614
(local vs general)
AVF, Arteriovenous fistula; AVG, arteriovenous graft.
Fig 4. Comparison of primary success for the various types
of vascular access procedures performed: AVF-U (12
months, n = 37; 24 months, n = 23), AVF-L (12 months, n
= 54; 24 months, n = 23), AVG-U,S (12 months, n = 18; 24
months, n = 6), AVG-Lp (12 months, n = 20; 24 months, n
= 5), AVG-S (12 months, n = 37; 24 months, n = 4). 
AVF, arteriovenous fistula, autogenous; AVG, arteriove-
nous graft, prosthetic; U, upper arm; L, lower arm; Lp,
loop graft; S, straight graft (only data with an SE less than
10% are shown).
Fig 5. Multivariate model (Cox regression), in which
access type (arteriovenous fistulae vs arteriovenous grafts;
P = .001) and presence or absence of diabetes mellitus (P
= .024) predict primary success. The four combinations of
the two variables (P = .001) and 2-year success are shown:
AVF-No DM (49% ± 2%), AVF-DM (37% ± 2%), AVG-No
DM (30% ± 3%), AVG-DM (19% ± 3%). 
AVF, arteriovenous fistula, autogenous; AVG, arteriove-
nous graft, prosthetic; DM, diabetes mellitus (only data
with an SE less than 10% are shown).
and patient education. The coordinator is central to
our program and is responsible for coordinating the
interaction among the three disciplines—vascular
surgery, nephrology, and interventional radiology.
We strongly believe that this program has stream-
lined care for vascular access patients. Such a multi-
disciplinary approach has been shown to result in a
marked decrease in hospitalization for access surgery,
with an associated reduction in cost.1 Likewise, we
found a substantial reduction in length of hospital
stay with the initiation of the vascular access pro-
gram, from 2.5 ± 0.06 days before (1994 and 1995)
to 1.1 ± 0.03 days after (1997 and 1998). 
This type of approach has been reported to
reduce the number of days patients are hospitalized
and the overall costs for creation of vascular access.8
More than 90% of access surgery in our program is
performed on a same-day discharge basis.
Approximately 5% of patients who initially were
planned for same-day discharge require admission, in
80% because of the unavailability of an escort home
and in the remainder because of bleeding or comor-
bid problems. The remaining patients have their
surgery as inpatients because of serious comorbidity.
Postoperative follow-up and assessment of inter-
current complications are also conducted in the
weekly access clinic. Specific access problems are dis-
cussed at monthly multidisciplinary access rounds
that are attended by the nurse coordinator, vascular
surgeons, nephrologists, and interventional radiolo-
gists, at which an agreed-on course is planned. 
The Vascular Access Work Group of the National
Kidney Foundation (NKF-Dialysis Outcomes
Quality Initiative, or NKF-DOQI) concluded in
1997 that outcomes for hemodialysis patients could
be significantly improved by increasing the place-
ment of native AVFs and detecting access dysfunction
before access thrombosis.9 The NKF-DOQI guide-
lines set out potential quality of care standards that
dialysis centers should follow. Because the autoge-
nous cephalic vein remains the superior conduit
when compared with a prosthetic,10 the proportion
of primary AVFs constructed in new patients enter-
ing hemodialysis should be at least 50%,9 a standard
that was met in our center. It has been reported that
women are more likely to undergo insertion of a
prosthetic graft than men, whereas men are more
likely to undergo creation of an AVF.11 Furthermore,
it has been shown that being female is a predictor of
failure for autogenous AVFs, but not prosthetic
AVGs.12 Among our patients, AVFs were created in
62% of men, but only 33% of women, which likely
relates to superior caliber arm veins in men. 
The algorithm we use for access site and type is
autogenous before prosthetic, nondominant arm
before dominant, and distal arm before proximal to
conserve sites. Only after these are exhausted would
we consider the lower extremity. An agreed-on
benchmark for the ideal proportion of AVFs
attempted that are suitable for efficient dialysis does
not exist. Some advocate attempting an AVF when-
ever a cephalic vein is found, regardless of size.13
The NKF-DOQI refuses to recommend an accept-
able guideline for primary AVF failure to encourage
native fistulae construction. Of the 235 AVFs per-
formed in our cohort, 11.5% did not mature suffi-
ciently to be useful for dialysis within 6 months. We
believe that this primary failure rate for AVFs is
acceptable, in light of the significant difference in
long-term results, and compares favorably with pre-
viously reported rates of primary failure of 8% to
24% for AVFs,14-16 and the recommended maximum
acceptable rates of primary failure of 5% to 15% for
AVGs.9 However, the option of reoperation should
not be taken lightly in this population of patients,
because of the psychological toll. 
Our results at 2 years support the use of AVFs vs
AVGs, with a primary success of 54% ± 4% and 18%
± 4%, respectively, which is in keeping with the other
reports that favor using not only the cephalic vein,
but also less commonly used autogenous veins to
maintain an all autogenous policy.11,13,17-20 Further-
more, the primary and secondary 2-year success
rates of 18% ± 4% and 60% ± 5% for AVGs also meet
NKF-DOQI guidelines9 and demonstrate the effec-
tiveness of our graft surveillance program in detect-
ing and correcting access stenoses before graft
thrombosis occurs. When comparing AVFs and
AVGs, the secondary success in our patients howev-
er, was not significantly different at 2 years (70% ±
4% and 60% ± 5%, respectively). Our results demon-
strated that 28.6% of AVGs underwent attempts for
secondary patency, compared with only 14% of
AVFs, which is related to interventions on patients
with complications of AVGs being more successful
than interventions on patients with AVFs.9,21
Our results indicated that the results in patients
with diabetes mellitus were inferior compared with
those in patients who do not have diabetes mellitus
(2-year success, 42% ± 4% vs 22% ± 5%, respective-
ly). The diabetic population is a challenge, because
of the greater likelihood of failure with any type of
access procedure. Giorcelli et al demonstrated that
patients with diabetes mellitus who have evidence of
vascular occlusive disease or other systemic diseases
or are older than 70 years had a decreased survival of
JOURNAL OF VASCULAR SURGERY
732 Kalman et al October 1999
their access, compared with patients with diabetes
mellitus who do not have these factors.22
In summary, the success of an access program in a
practical and cost-effective way depends only partially
on the vascular surgeon, who serves an important
technical role, ensuring the success of a particular
access site. The organization of a vascular access pro-
gram in a practical and cost-effective way for reduced
length of hospital stay is streamlined through a dedi-
cated access coordinator who ensures an integrated,
multidisciplinary approach. The results of the Cox
proportional hazards multivariate analysis created a
model of two variables (access type [AVF vs AVG] and
presence or absence of diabetes mellitus) that were
independently predictive of primary success. Models
such as these are useful when discussing the anticipat-
ed results of access procedures with individual patients.
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